Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company specializing in curative targeted cell therapies for autoimmune diseases, has announced its upcoming participation in Guggenheim's SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
Interested parties can access a live webcast of the presentation through the News and Events section of Cabaletta Bio's website. The presentation recording will remain available for replay on the company's website for 30 days following the event.
Cabaletta Bio (Nasdaq: CABA), una azienda biotecnologica in fase clinica specializzata in terapie cellulari mirate curative per malattie autoimmuni, ha annunciato la propria partecipazione imminente alla SMID Cap Biotech Conference di Guggenheim. L'azienda parteciperà a una chiacchierata informale programmata per mercoledì 5 febbraio 2025, alle 10:30 ET a New York, NY.
Le parti interessate possono accedere a una trasmissione web in diretta della presentazione attraverso la sezione Notizie ed Eventi del sito web di Cabaletta Bio. La registrazione della presentazione rimarrà disponibile per la visione on-demand sul sito dell'azienda per 30 giorni dopo l'evento.
Cabaletta Bio (Nasdaq: CABA), una empresa de biotecnología en etapa clínica que se especializa en terapias celulares dirigidas y curativas para enfermedades autoinmunes, ha anunciado su próxima participación en la Conferencia de Biotecnología SMID Cap de Guggenheim. La empresa estará presente en una charla informal programada para el miércoles 5 de febrero de 2025, a las 10:30 a.m. ET en Nueva York, NY.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Noticias y Eventos del sitio web de Cabaletta Bio. La grabación de la presentación estará disponible para su reproducción en el sitio de la empresa durante 30 días después del evento.
카발레타 바이오 (Nasdaq: CABA), 자가면역 질환을 위한 치료적 표적 세포 요법에 전문화된 임상 단계 생명공학 회사는 구겐하임의 SMID Cap 생명공학 컨퍼런스에 참여할 예정이라고 발표했습니다. 이 회사는 2025년 2월 5일 수요일, 오전 10시 30분 ET에 뉴욕에서 예정된 파이어사이드 채팅에 참여할 것입니다.
관심 있는 분들은 카발레타 바이오 웹사이트의 뉴스 및 이벤트 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 30일 동안 회사 웹사이트에서 재생할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies cellulaires ciblées curatives pour les maladies auto-immunes, a annoncé sa participation prochaine à la Conférence SMID Cap Biotech de Guggenheim. L'entreprise participera à une discussion informelle prévue pour mercredi 5 février 2025 à 10h30 ET à New York, NY.
Les parties intéressées peuvent accéder à une diffusion web en direct de la présentation via la section Actualités et Événements du site web de Cabaletta Bio. L'enregistrement de la présentation restera disponible en rediffusion sur le site de l'entreprise pendant 30 jours suivant l'événement.
Cabaletta Bio (Nasdaq: CABA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf kurative zielgerichtete Zelltherapien für Autoimmunerkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der SMID Cap Biotech Conference von Guggenheim bekannt gegeben. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der für Mittwoch, den 5. Februar 2025, um 10:30 Uhr ET in New York, NY, geplant ist.
Interessierte Parteien können eine Live-Übertragung der Präsentation über den Nachrichten- und Veranstaltungsbereich der Cabaletta Bios Webseite abrufen. Die Aufzeichnung der Präsentation bleibt 30 Tage nach der Veranstaltung auf der Website des Unternehmens für eine Wiederholung verfügbar.
- None.
- None.
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
When is Cabaletta Bio (CABA) presenting at Guggenheim's SMID Cap Biotech Conference 2025?
How can investors watch Cabaletta Bio's (CABA) Guggenheim Conference presentation?
How long will Cabaletta Bio's (CABA) Guggenheim Conference presentation be available for replay?
What type of therapies is Cabaletta Bio (CABA) developing?
